Aerami’s upcoming merger with FoxWayne will bolster the company’s PAH portfolio
Proceeds from Aerami’s merger with FoxWayne will help advance the development of the company’s PAH therapy, AER-901 (imatinib).
By
M&A Review Financial Advisor League Tables - Academic
Latest in
M&A Review Financial Advisor League Tables - Academic
Aerami’s upcoming merger with FoxWayne will bolster the company’s PAH portfolio
Proceeds from Aerami’s merger with FoxWayne will help advance the development of the company’s PAH therapy, AER-901 (imatinib).
By
Alvotech and Oaktree enter merger deal to form biopharma company
To be valued at nearly $2.25bn, the combined firm is expected to invest in boosting the biosimilar pipeline.
Drug developer BenevolentAI enters SPAC merger deal with Odyssey
The merged company will be headquartered in London and led by the current CEO of BenevolentAI.
Amgen concludes acquisition of biotech company Teneobio for $2.5bn
Teneobio’s three affiliates, TeneoTwo, TeneoFour and TeneoTen, were spun off to its present equity holders.
Sanofi concludes acquisition of Translate Bio for $3.2bn
Sanofi expects the deal to be vital for its mRNA Center of Excellence to unravel mRNA vaccines’ potential.
EQRx signs $1.8bn merger deal with CM Life Sciences III
The funds from the deal will be utilised to build a clinical development organisation that develops low-price novel treatments.
AstraZeneca concludes Alexion acquisition for $39bn
Alexion’s complement-biology platform and pipeline are to be used by AstraZeneca to develop treatments for rare diseases.